Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 1 month ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Apabetalone: Evidence and Outcomes Related to Cardiovascular Health
Author(s): Yimeng Zhang , Nimai Desai , Derek Connolly Added: 2 months ago

Prevention & Chronic Conditions

CV Disease in Special Populations
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 3 days ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Renal Metabolic

Heart Failure
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Luis Castilla-Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s): Joshua Stolker , Philippe Gabriel Steg , Roberta Rossini , et al Added: 1 week ago

COVID-19

MI/ACS
The FISH&CHIPS Study: Real-world Study Reveals Significant Reduction in All-cause and Cardiovascular Mortality
Author(s): Jonathon A Leipsic Added: 1 year ago
FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).A 14%… View more

Guidelines & Statements

Imaging & Diagnostics
ACC 2025: EVOLUT Low Risk 5Y Outcomes
Author(s): Michael J Reardon Added: 1 month ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more

Intervention
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 1 month ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Renal Metabolic
CardioNerds @AHA23: ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin
Author(s): Naima Maqsood , Jeff Healey Added: 1 year ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of… View more

Anticoagulation

Electrophysiology & Arrhythmia
Remnant Lipoproteins and ASCVD
Author(s): Mohanad Gabani , Michael D Shapiro , Peter P Toth Added: 1 year ago

Prevention & Chronic Conditions